A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1) - Wikidata - awgldk - TriplyDB

A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)

A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)

http://www.wikidata.org/entity/Q33394828

about

Albumin-bound paclitaxel in solid tumors: clinical development and future directions Optimal management of metastatic melanoma: current strategies and future directions Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics Drug delivery nanoparticles in skin cancers Clinical Translation of Nanomedicine.A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775 The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.Therapy for metastatic melanoma: the past, present, and future.Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.Vulvar melanoma with urethral invasion and bladder metastases - a case report and review of the literature The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma.Chemotherapy in the management of advanced cutaneous malignant melanoma.Metastatic melanoma - a review of current and future drugs Current status of primary malignant melanoma of the esophagus: clinical features, pathology, management and prognosis.Advances in cutaneous melanoma.Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics.Nab-paclitaxel in patients with metastatic melanoma.Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.Is Age ≥ 70 Years an Important Predictor of Adverse Events Among Patients Enrolled in Metastatic Melanoma Trials? Findings from Pooled Analyses of Therapeutic Trials.Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?Neoadjuvant systemic therapy for regionally advanced melanoma.Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.The role of chemotherapy in the modern management of melanoma

P2860

Q26798674-75B0D01B-522D-4F34-A70A-44894EB71C13 Q26997338-8C51E63A-F50A-4C3C-AE3B-BF08C2418624 Q27027238-7106BBC5-409C-45D8-886D-DCF2558187AE Q28390405-25BEB829-E563-4D22-9C6D-743811763E68 Q30355939-DC5D2BC1-A9A9-4E30-8DE0-D48696B9F77F Q33405667-130E90D1-7505-45AD-9216-75E3CFB0BC00 Q33411962-84AE5CF3-15F7-4AE6-B481-217349291A03 Q33435722-CCB2493B-58E0-479B-ACF2-A885A7463814 Q33435812-79B8243C-E5AF-4685-8A63-E9B7BE6D9CFA Q33667485-C55E29A7-968B-40E0-A600-BE31D735042F Q33871014-89845C50-4170-4450-B500-4AA057F753AC Q34086875-06ECD5EA-2DE8-4271-BA2C-619EE380CD0A Q34183225-47FC6642-44CF-4A30-BD03-293DC4FD8F7A Q34608899-8476BC55-0FD1-4A51-B312-2D2F5B828486 Q34781518-961DB263-7CBE-4FE3-9C20-11F4754EA429 Q35041273-0F658207-CEF0-4DE4-842D-41755FE4E97B Q35232206-654A2EFC-B1F4-4F2C-AAC9-7639C0BCE7A4 Q35475284-60AC49DC-738B-4FFC-A554-87442EA5AE8B Q36040758-DB466EC0-F401-45AA-8175-99BAA668E897 Q36213487-796A514B-C4C5-4731-8A56-C855BD129888 Q36860835-0CC51532-7872-43DC-B957-372C5E815349 Q36887861-355E206D-7544-4CCD-947F-4722BC8F69C7 Q37007984-577E57CD-271D-4173-9450-058C4EE12EF7 Q37450733-7D2D3698-7F43-4B08-808F-B891D49A899E Q37952081-17D33FC4-C045-4A94-BB69-AF8AA23F0DA1 Q38007036-CA2474EA-179D-46AB-A33D-C15A613434DF Q38127412-CB438B91-3D1A-4F20-8FC4-D39BBFBC7D98 Q38625186-81D3E86F-67CA-4815-9434-DE24FB1351EE Q39562562-BEDE7F7D-A9EA-4E7F-B522-B97D33489C01 Q41113378-7024C2AE-F83C-4B53-A7FA-06C4931B34C4 Q41536996-0B308428-A7A5-453A-BD1E-EE03537B6217 Q43613760-04A90ACD-E37F-44EC-959D-8795AF415300 Q47329770-EFE2637A-ABDD-4FAB-9D90-1186DE0A8C84 Q52730051-D8F93492-D6CA-47CB-BE40-E4A3EF3FC319 Q57569574-FD507483-A2EF-4108-BCEB-604EDADE6DD0

P2860

A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)

http://www.wikidata.org/entity/Q33394828

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase II trial of nab-paclit ...... reatment Group Study, N057E(1)

@ast

A phase II trial of nab-paclit ...... reatment Group Study, N057E(1)

@en

type

label

A phase II trial of nab-paclit ...... reatment Group Study, N057E(1)

@ast

A phase II trial of nab-paclit ...... reatment Group Study, N057E(1)

@en

prefLabel

A phase II trial of nab-paclit ...... reatment Group Study, N057E(1)

@ast

A phase II trial of nab-paclit ...... reatment Group Study, N057E(1)

@en

P1433

Q33394828-4C4C3F75-71FE-40FB-A12C-4CCE763FFC07

P1476

Q33394828-A0858B92-A771-429E-944F-CEF8D6C93337

P2093

Q33394828-025F91FA-C408-4387-8113-CC4CD7853C3C

Q33394828-0F08A972-5FDD-4DEF-A08C-A8235302A5E3

Q33394828-141A3326-05DC-42B8-84A5-79D5AD195660

Q33394828-229DFBA3-2623-4CAE-83AA-CF79F5DA3A80

Q33394828-26A2AF54-DD2D-49E2-A833-DDA3F2C9E798

Q33394828-588B57F3-7E95-4C42-8F03-C2751050E204

Q33394828-8732B61D-B650-4726-87C7-22618E5AF216

Q33394828-8EE6FB45-C1F3-43FD-820A-D50163887577

Q33394828-BD26678C-1475-48F7-8A79-9C17B8B7F67C

Q33394828-FF160171-2384-4299-AC3D-6FB33A43A937

P2860

Q33394828-087D2AFA-6BAE-42AA-A70A-4A9938806D30

Q33394828-154C4AD7-7187-417F-90A9-928AE1724FCD

Q33394828-23EA6C68-85FA-4F78-9220-73F2B35D3088

Q33394828-3B67CC64-1313-4937-B3D2-113EA2EF3E42

Q33394828-45B8198D-48D8-4299-B3B1-DAF44FE8ADF7

Q33394828-5ADAC5F2-3C0E-40D7-B805-0BED5D873FC8

Q33394828-8512BFFA-2C5D-498C-98D8-31D5147A2DB0

Q33394828-8C456D17-0128-40D3-A958-BBD237584CDF

Q33394828-8E2604F1-A899-461B-9C34-52A1A06D3E58

Q33394828-A9181BF4-7FD3-46B3-8402-795E5D395B47

P304

Q33394828-A1D02689-C4F5-4063-8729-200B8BAB1602

P31

Q33394828-7BD716EF-A488-4C70-88E8-A89BC036A197

P356

Q33394828-A8169974-9C67-4847-B5F8-927E5759C2DB

P407

Q33394828-B7283004-BBCF-4D2A-AD84-3C1C9FE64959

P433

Q33394828-FAD30BE5-2499-4C52-B111-C2865EF15421

P478

Q33394828-378CD9B2-7544-4CEF-89EA-148592198447

P577

Q33394828-368BF7A7-CA00-4A5C-8BA9-97354A5497CA

P5875

Q33394828-FB36DB5C-3FC2-463D-9CBE-6FD8893C959D

P698

Q33394828-2284CC69-76AF-4585-8E19-13F015946028

P921

Q33394828-6ACD27A3-44FA-4506-82ED-B4CE2CC0910D

P932

Q33394828-A8B8EC64-3D10-4325-9898-29FD8ED94678

P356

P1433

P1476

A phase II trial of nab-paclit ...... reatment Group Study, N057E(1)

@en

P2093

Anthony J Jaslowski

http://www.w3.org/2001/XMLSchema#string

Bassam I Mattar

http://www.w3.org/2001/XMLSchema#string

Daniel A Nikcevich

http://www.w3.org/2001/XMLSchema#string

Lisa A Kottschade

http://www.w3.org/2001/XMLSchema#string

Robert Behrens

http://www.w3.org/2001/XMLSchema#string

Robert R McWilliams

http://www.w3.org/2001/XMLSchema#string

Svetomir N Markovic

http://www.w3.org/2001/XMLSchema#string

Thomas Amatruda

http://www.w3.org/2001/XMLSchema#string

Tom R Fitch

http://www.w3.org/2001/XMLSchema#string

Vera J Suman

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma.

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.

Desmoids in familial adenomatous polyposis are monoclonal proliferations.

Prognostic factors in 1,521 melanoma patients with distant metastases.

Phase II study of paclitaxel and carboplatin for malignant melanoma.

P304

1704-1710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25659

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51031981

http://www.w3.org/2001/XMLSchema#string

P698

21472717

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3116030

http://www.w3.org/2001/XMLSchema#string